Amyl Therapeutics
Amyl Therapeutics is developing immunotherapies that target amyloid aggregates linked to neurodegenerative disease.
€8.3MSeries A extension
ParticipantME
Mérieux Equity Partners
Activity from announced rounds
Activity in this selectionOct 24, 2026 · Biotech · Jul 27, 2026
- Rounds participated in
- 1
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $9.6M 1 disclosed · full round size, not this investor’s share